BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tramsen L, Schmidt S, Roeger F, Schubert R, Salzmann-Manrique E, Latgé JP, Klingebiel T, Lehrnbecher T. Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect Immun 2014;82:2649-56. [PMID: 24711569 DOI: 10.1128/IAI.01700-14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Wang R, Wang H, Yang X, Yang J, Xiong W, Wen Q, Ma L. Glucocorticoids Suppress Antimicrobial Autophagy and Nitric Oxide Production and Facilitate Mycobacterial Survival in Macrophages. Sci Rep 2017;7:982. [PMID: 28428627 DOI: 10.1038/s41598-017-01174-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
2 Lauruschkat CD, Einsele H, Loeffler J. Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives. J Fungi (Basel) 2018;4:E137. [PMID: 30558125 DOI: 10.3390/jof4040137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
3 Wurster S, Albert ND, Bharadwaj U, Kasembeli MM, Tarrand JJ, Daver N, Kontoyiannis DP. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Front Immunol 2022;13:838344. [DOI: 10.3389/fimmu.2022.838344] [Reference Citation Analysis]
4 Schmidt S, Schubert R, Demir A, Lehrnbecher T. Distinct Effects of Immunosuppressive Drugs on the Anti-Aspergillus Activity of Human Natural Killer Cells. Pathogens 2019;8:E246. [PMID: 31752374 DOI: 10.3390/pathogens8040246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sam QH, Yew WS, Seneviratne CJ, Chang MW, Chai LYA. Immunomodulation as Therapy for Fungal Infection: Are We Closer? Front Microbiol 2018;9:1612. [PMID: 30090091 DOI: 10.3389/fmicb.2018.01612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
6 Ademe M. Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges. Front Cell Infect Microbiol 2020;10:469. [PMID: 33042859 DOI: 10.3389/fcimb.2020.00469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Posch W, Wilflingseder D, Lass-flörl C. Immunotherapy as an Antifungal Strategy in Immune Compromised Hosts. Curr Clin Micro Rpt 2020;7:57-66. [DOI: 10.1007/s40588-020-00141-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Deo SS, Gottlieb DJ. Adoptive T-cell therapy for fungal infections in haematology patients. Clin Transl Immunology 2015;4:e40. [PMID: 26366286 DOI: 10.1038/cti.2015.16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
9 Thammasit P, Sripetchwandee J, Nosanchuk JD, Chattipakorn SC, Chattipakorn N, Youngchim S. Cytokine and Chemokine Responses in Invasive Aspergillosis Following Hematopoietic Stem Cell Transplantation: Past Evidence for Future Therapy of Aspergillosis. J Fungi (Basel) 2021;7:753. [PMID: 34575791 DOI: 10.3390/jof7090753] [Reference Citation Analysis]
10 Dutta O, Masso-Silva JA, Wang K, Rivera A. Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus. Curr Pharmacol Rep 2017;3:335-45. [PMID: 29430385 DOI: 10.1007/s40495-017-0111-4] [Reference Citation Analysis]
11 Schmidt S, Hogardt M, Demir A, Röger F, Lehrnbecher T. Immunosuppressive Compounds Affect the Fungal Growth and Viability of Defined Aspergillus Species. Pathogens 2019;8:E273. [PMID: 31795350 DOI: 10.3390/pathogens8040273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]